CPIX
CUMBERLAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.44
+3.02%Nov 3, 2026, 21:05 UTC
CUMBERLAND PHARMACEUTICALS INC announced that it will release its third-quarter 2026 financial results after the market closes on November 10, 2026.
Source:Oct 23, 2026, 20:05 UTC
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis, reporting that the drug was well tolerated.
Source:Oct 19, 2026, 20:05 UTC
Cumberland Pharmaceuticals announced that it will present an update on its ifetroban DMD program on a national call.
Source:Aug 4, 2026, 21:06 UTC
Cumberland Pharmaceuticals funded a special shareholder dividend.
Source:Jul 13, 2026, 14:46 UTC
Cumberland Pharmaceuticals Inc. declared a special cash dividend of $1.50 per share.
Jul 1, 2026, 13:00 UTC
Cumberland Pharmaceuticals closed a strategic transaction with Apotex to integrate their branded U.S. businesses.